Company registration number: 14055900
Unaudited financial statements
for the period ended 31 July 2024
for
Nadbiotech Ltd
Pages for filing with the Registrar
Company registration number: 14055900
Nadbiotech Ltd
Balance sheet
as at 31 July 2024
31 Jul 24 30 Apr 23
Note £ £ £ £
Fixed assets
Intangible assets 4 1,367,022 1,144,168
1,367,022 1,144,168
Creditors: amounts falling due within one
year
(1,366,922) (1,144,068)
Net current liabilities (1,366,922) (1,144,068)
Total assets less current liabilities 100 100
NET ASSETS 100 100
Capital and reserves
Called up share capital 100 100
TOTAL EQUITY 100 100
The company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies for the period ended 31 July 2024.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges their responsibilities to comply with the Companies Act 2006 in respect to accounting records and the preparation of financial statements.
The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
In accordance with Section 444 of the Companies Act 2006, the Profit and loss account has not been delivered to the Registrar.
Signed by:
Ms Y Feng, Director
27 May 2025
1
Nadbiotech Ltd
Notes to the financial statements
for the period ended 31 July 2024
1 Company information
Nadbiotech Ltd is a private company registered in England and Wales. Its registered number is 14055900. The company is limited by shares. Its registered office is 27 Wimpole Street, London, W1G 8GN.
2 Accounting policies
Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” including the provisions of Section 1A “Small Entities” and the Companies Act 2006. The financial statements have been prepared under the historic cost convention.
Going concern
In preparing these financial statements, the director has assessed whether there are any material uncertainties related to events or conditions that cast significant doubt upon the company's ability to continue as a going concern. In making this assessment, the director takes into account all available information about the future which is at least 12 months from the date that the financial statements are authorised for issue.
The director considers that the company has adequate resources to continue in business for the foreseeable future and that it is appropriate to adopt the going concern basis in preparing the financial statements.
Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
Amortisation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Development costs - Straight line over life of asset, starting for completion of
asset
3 Average number of employees
During the period the average number of employees was 1 (2023 - 1).
2
Nadbiotech Ltd
Notes to the financial statements - continued
for the period ended 31 July 2024
4 Intangible assets
Other
intangible
assets
£
Cost
At 1 May 2023 1,144,168
Additions 222,854
At 31 July 2024 1,367,022
Amortisation
At 31 July 2024 -
Net book value
At 31 July 2024 1,367,022
At 30 April 2023 1,144,168
3